» Articles » PMID: 23415394

Monoaminergic Dysfunction in Recreational Users of Dexamphetamine

Overview
Publisher Elsevier
Specialties Pharmacology
Psychiatry
Date 2013 Feb 19
PMID 23415394
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Preclinical studies suggest that dexamphetamine (dAMPH) can lead to monoaminergic neurotoxicity. This exploratory study aimed to investigate effects of recreational dAMPH use on the dopamine (DA) and noradrenaline (NA) systems in humans. To that purpose, eight male abstinent dAMPH (26.0 ± 4.0 years) users and 10 age- and IQ-matched male healthy control subjects (23.0 ± 3.8) underwent neuropsychological testing sensitive to DAergic function and single photon emission computed tomography (SPECT) scanning with [(123)I]FP-CIT to determine striatal DA transporter (DAT) binding. In addition, changes in cerebral blood flow (CBF) induced by the DA/NA reuptake inhibitor methylphenidate (MPH) were measured using pharmacological magnetic resonance imaging (phMRI). Performance of dAMPH users was significantly worse on executive function and verbal memory tasks. Striatal DAT binding ratios were on average lower in dAMPH users (near-significant, p=0.05). In addition, CBF in control subjects decreased significantly in response to MPH in gray matter and basal ganglia, among which the striatum, thalamus and hippocampus by 10% to 29%. However, in dAMPH users the CBF response was blunted in most brain areas studied, only decreasing in the hippocampus and orbitofrontal cortex. When comparing groups, CBF response was found to be significantly different in the thalamus with a decrease for healthy controls and a blunted response in dAMPH users. Collectively, our findings of a blunted hemodynamic response in monoaminergic regions, in combination with indications for lower striatal DAT binding and poorer behavioral measures are likely to represent DAergic dysfunction in dAMPH users, although NAergic dysfunction may also play a role.

Citing Articles

The influence of drug class on reward in substance use disorders.

Jones J, Arout C, Luba R, Murugesan D, Madera G, Gorsuch L Pharmacol Biochem Behav. 2024; 240():173771.

PMID: 38670466 PMC: 11162950. DOI: 10.1016/j.pbb.2024.173771.


Acute drug effects differentially predict desire to take dextroamphetamine again for work and recreation.

Hoots J, Webber H, Nunez C, Cooper J, Lopez-Gamundi P, Lawlor V Psychopharmacology (Berl). 2021; 238(10):2815-2826.

PMID: 34137904 DOI: 10.1007/s00213-021-05897-6.


Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis.

Ashok A, Mizuno Y, Volkow N, Howes O JAMA Psychiatry. 2017; 74(5):511-519.

PMID: 28297025 PMC: 5419581. DOI: 10.1001/jamapsychiatry.2017.0135.


Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.

Schrantee A, Tremoleda J, Wylezinska-Arridge M, Bouet V, Hesseling P, Meerhoff G PLoS One. 2017; 12(2):e0172776.

PMID: 28241065 PMC: 5328278. DOI: 10.1371/journal.pone.0172776.


Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Kish S, Boileau I, Callaghan R, Tong J Eur J Neurosci. 2016; 45(1):58-66.

PMID: 27519465 PMC: 5209286. DOI: 10.1111/ejn.13363.